Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Part, Randomized Study of Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers

Trial Profile

A Two Part, Randomized Study of Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dermacyte liquid (Primary)
  • Indications Varicose ulcer
  • Focus Adverse reactions
  • Sponsors Merakris Therapeutics

Most Recent Events

  • 27 Mar 2025 Interim results presented in a Merakris Therapeutics media release
  • 27 Mar 2025 According to Merakris Therapeutics media release, company announced the publication of positive clinical trial results from the first part of its ongoing Phase 2, multicenter trial. Interim results from part one of the study published in the International Wound Journal.
  • 10 Dec 2024 According to Merakris Therapeutics media release, company announced that enrollment is now open for Part 2 of its Phase 2 multicenter, clinical trial. Trial will enroll patients across approximately 10 medical centers in the United States with dosing to begin immediately. Company is targeting late-2025 for completion of the study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top